Welcome to our dedicated page for INTEST SEC filings (Ticker: INTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INTEST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INTEST's regulatory disclosures and financial reporting.
BlackRock, Inc. reports a passive ownership stake in INTEST CORP common stock on a Schedule 13G. BlackRock states that it beneficially owns 824,291 shares, representing 6.6% of the outstanding common stock.
BlackRock reports sole voting power814,108 shares and sole dispositive power824,291 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no single client holds more than five percent of INTEST CORP’s total outstanding shares.
INTEST CORP director Steven J. Abrams reported a non-market gift transfer of common stock. On July 9, 2026, he transferred 3,000 shares of common stock for no consideration to a family trust of which he and his spouse are co-trustees. Following the transactions, he reports 6,000 shares held directly and 102,000 shares held indirectly through the Steven J. Abrams Revocable Trust, and he remains the beneficial owner of the shares held by the trust.
INTEST CORP director Steven J. Abrams reported a gift transfer of 3,000 shares of common stock. On June 29, 2026, he transferred these shares to a family trust for no consideration, characterized as a bona fide gift. After the transaction, he directly holds 9,000 shares and indirectly holds 99,000 shares through the Steven J. Abrams Revocable Trust. The filing states he and his spouse are co-trustees of the family trust and that he remains the beneficial owner of the shares held by that trust, so this is not an open-market sale and does not change his overall economic exposure to INTEST CORP.
INTEST CORP director Karl E. Johnsen reported receiving equity compensation in the form of restricted common shares. On June 17, 2026, he was granted 12,000 restricted shares that will vest in two equal parts on September 30, 2026 and December 31, 2026.
He was also granted 6,000 additional restricted shares that will vest in four equal annual installments beginning on June 17, 2027. These awards were granted at no cash cost to him under the InTest Corporation 2023 Stock Incentive Plan and represent non‑market, compensation-related acquisitions rather than open‑market purchases or sales.
INTEST CORP director Karl E. Johnsen has filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing lists him as a director but does not report any share purchases, sales, or other transactions at this time.
INTEST CORP director Gerald J. Maginnis reported a disposition of 6,000 shares of Common Stock back to the company. This was recorded as a "Disposition to issuer" with a stated price of $0.00 per share. After the transaction, he directly holds 90,057 shares.
InTest Corporation held its 2026 Annual Meeting of Stockholders on June 17, 2026, where a quorum of 9,494,132 shares was present out of 12,548,356 shares outstanding as of the April 20, 2026 record date. Stockholders elected five directors to serve until the next annual meeting, each receiving a majority of votes cast. They also approved Amendment No. 1 to the InTest Corporation 2023 Stock Incentive Plan and ratified RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on an advisory basis, the compensation of the company’s named executive officers.
inTEST Corporation reported stronger results for the quarter ended March 31, 2026. Revenue rose to $33.9 million from $26.6 million a year earlier, driven across semiconductor, Auto/EV, defense/aerospace and life sciences markets. The company swung to net earnings of $0.8 million from a loss of $2.3 million, though operating cash flow moved to a use of $3.3 million from prior positive cash generation. Total assets were $150.8 million, including $12.9 million of cash and cash equivalents and $30.5 million of inventories. Share count remained stable, with 12.56 million common shares outstanding as of April 30, 2026.
InTest Corporation reported strong first quarter 2026 results with revenue of $33.9 million, up 27.2% year-over-year. Gross margin improved to 45.5%, and net earnings reached $0.8 million, or $0.06 per diluted share, compared with a loss a year ago. Non-GAAP adjusted EPS was $0.16 and adjusted EBITDA was $3.2 million, reflecting better volume, product mix and cost control.
Orders were $31.8 million, up 25.4% year-over-year, and backlog grew to $51.8 million, 35.5% higher than a year earlier. The company raised full-year 2026 revenue guidance to $130 million–$135 million and now expects about 45% gross margin and operating expenses of $55 million–$57 million. In a separate move, InTest amended its loan agreement with M&T Bank, extending the period to draw on its term loan facility to August 28, 2026.
inTEST Corp reports an institutional owner holding 681,913 shares. Vanguard Capital Management filed a Schedule 13G reporting 5.45% of the common stock, with sole dispositive power over 681,913 shares and sole voting power for 76,387 shares. The filing is signed by Ashley Grim on 04/30/2026.